400 related articles for article (PubMed ID: 21626049)
1. A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen).
Reni M; Cereda S; Rognone A; Belli C; Ghidini M; Longoni S; Fugazza C; Rezzonico S; Passoni P; Slim N; Balzano G; Nicoletti R; Cappio S; Doglioni C; Villa E
Cancer Chemother Pharmacol; 2012 Jan; 69(1):115-23. PubMed ID: 21626049
[TBL] [Abstract][Full Text] [Related]
2. Real-world outcomes of cisplatin, capecitabine, and gemcitabine with either epirubicin (PEXG) or docetaxel (PDXG) as first-line palliative treatment in metastatic or unresectable locally advanced pancreatic adenocarcinoma.
Hitchen N; Waldron NR; Deva S; Findlay M; Lawrence B
Asia Pac J Clin Oncol; 2023 Oct; 19(5):e231-e238. PubMed ID: 36114593
[TBL] [Abstract][Full Text] [Related]
3. Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma.
Reni M; Cereda S; Bonetto E; ViganĂ² MG; Passoni P; Zerbi A; Balzano G; Nicoletti R; Staudacher C; Di Carlo V
Cancer Chemother Pharmacol; 2007 Feb; 59(3):361-7. PubMed ID: 16807732
[TBL] [Abstract][Full Text] [Related]
4. PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) regimen as second-line therapy in patients with progressive or recurrent pancreatic cancer after gemcitabine-containing chemotherapy.
Reni M; Cereda S; Mazza E; Passoni P; Nicoletti R; Balzano G; Zerbi A; Arcidiacono PG; Staudacher C; Di Carlo V
Am J Clin Oncol; 2008 Apr; 31(2):145-50. PubMed ID: 18391598
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) or gemcitabine followed by chemoradiation in pancreatic cancer: a randomized phase II trial.
Reni M; Balzano G; Aprile G; Cereda S; Passoni P; Zerbi A; Tronconi MC; Milandri C; Saletti P; Rognone A; Fugazza C; Magli A; Di Muzio N; Di Carlo V; Villa E
Ann Surg Oncol; 2012 Jul; 19(7):2256-63. PubMed ID: 22237835
[TBL] [Abstract][Full Text] [Related]
6. The cisplatin, epirubicin, 5-fluorouracil, gemcitabine (PEFG) regimen in advanced biliary tract adenocarcinoma.
Cereda S; Passoni P; Reni M; ViganĂ² MG; Aldrighetti L; Nicoletti R; Villa E
Cancer; 2010 May; 116(9):2208-14. PubMed ID: 20187098
[TBL] [Abstract][Full Text] [Related]
7. Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial.
Reni M; Cordio S; Milandri C; Passoni P; Bonetto E; Oliani C; Luppi G; Nicoletti R; Galli L; Bordonaro R; Passardi A; Zerbi A; Balzano G; Aldrighetti L; Staudacher C; Villa E; Di Carlo V
Lancet Oncol; 2005 Jun; 6(6):369-76. PubMed ID: 15925814
[TBL] [Abstract][Full Text] [Related]
8. Outcome of upfront combination chemotherapy followed by chemoradiation for locally advanced pancreatic adenocarcinoma.
Reni M; Cereda S; Balzano G; Passoni P; Rognone A; Zerbi A; Nicoletti R; Mazza E; Arcidiacono PG; Di Carlo V; Villa E
Cancer Chemother Pharmacol; 2009 Nov; 64(6):1253-9. PubMed ID: 19381632
[TBL] [Abstract][Full Text] [Related]
9. Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904.
Kulke MH; Tempero MA; Niedzwiecki D; Hollis DR; Kindler HL; Cusnir M; Enzinger PC; Gorsch SM; Goldberg RM; Mayer RJ
J Clin Oncol; 2009 Nov; 27(33):5506-12. PubMed ID: 19858396
[TBL] [Abstract][Full Text] [Related]
10. PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) for patients with advanced pancreatic cancer: the ghost regimen.
Reni M; Cereda S; Galli L
Cancer Lett; 2007 Oct; 256(1):25-8. PubMed ID: 17561341
[TBL] [Abstract][Full Text] [Related]
11. Modified docetaxel and cisplatin in combination with capecitabine (DCX) as a first-line treatment in HER2-negative advanced gastric cancer.
Bilici A; Selcukbiricik F; Demir N; Oven Ustaalioglu BB; Dikilitas M; Yildiz O
Asian Pac J Cancer Prev; 2014; 15(20):8661-6. PubMed ID: 25374186
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of capecitabine plus docetaxel in gemcitabine-pretreated metastatic pancreatic cancer patients: CapTere.
Soares HP; Bayraktar S; Blaya M; Lopes G; Merchan J; Macintyre J; Mayo C; Green MR; Silva O; Levi J; Walker G; Rocha-Lima CM
Cancer Chemother Pharmacol; 2014 Apr; 73(4):839-45. PubMed ID: 24562589
[TBL] [Abstract][Full Text] [Related]
13. A phase I study of the biomodulation of capecitabine by docetaxel and gemcitabine (mGTX) in previously untreated patients with metastatic adenocarcinoma of the pancreas.
Hill ME; Li X; Kim S; Campbell A; Culler K; Bloomston M; Zalupski M; Hejna G; Bekaii-Saab T
Cancer Chemother Pharmacol; 2011 Mar; 67(3):511-7. PubMed ID: 20461379
[TBL] [Abstract][Full Text] [Related]
14. Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial.
Reni M; Zanon S; Peretti U; Chiaravalli M; Barone D; Pircher C; Balzano G; Macchini M; Romi S; Gritti E; Mazza E; Nicoletti R; Doglioni C; Falconi M; Gianni L
Lancet Gastroenterol Hepatol; 2018 Oct; 3(10):691-697. PubMed ID: 30220407
[TBL] [Abstract][Full Text] [Related]
15. Definitive results of a phase II trial of cisplatin, epirubicin, continuous-infusion fluorouracil, and gemcitabine in stage IV pancreatic adenocarcinoma.
Reni M; Passoni P; Panucci MG; Nicoletti R; Galli L; Balzano G; Zerbi A; Di Carlo V; Villa E
J Clin Oncol; 2001 May; 19(10):2679-86. PubMed ID: 11352960
[TBL] [Abstract][Full Text] [Related]
16. Docetaxel second-line therapy in patients with advanced pancreatic cancer: a retrospective study.
Saif MW; Syrigos K; Penney R; Kaley K
Anticancer Res; 2010 Jul; 30(7):2905-9. PubMed ID: 20683031
[TBL] [Abstract][Full Text] [Related]
17. A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma.
Evans TR; Pentheroudakis G; Paul J; McInnes A; Blackie R; Raby N; Morrison R; Fullarton GM; Soukop M; McDonald AC
Ann Oncol; 2002 Sep; 13(9):1469-78. PubMed ID: 12196374
[TBL] [Abstract][Full Text] [Related]
18. Second-line chemotherapy with capecitabine (Xeloda) and docetaxel (Taxotere) in previously treated, unresectable adenocarcinoma of pancreas: the final results of a phase II trial.
Katopodis O; Polyzos A; Kentepozidis N; Giassas S; Rovithi M; Bozionelou V; Kalbakis K; Vamvakas L; Mavroudis D; Georgoulias V
Cancer Chemother Pharmacol; 2011 Feb; 67(2):361-8. PubMed ID: 20428874
[TBL] [Abstract][Full Text] [Related]
19. A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma.
De Jesus-Acosta A; Oliver GR; Blackford A; Kinsman K; Flores EI; Wilfong LS; Zheng L; Donehower RC; Cosgrove D; Laheru D; Le DT; Chung K; Diaz LA
Cancer Chemother Pharmacol; 2012 Feb; 69(2):415-24. PubMed ID: 21800112
[TBL] [Abstract][Full Text] [Related]
20. Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma: a dose-finding study.
Reni M; Cereda S; Bonetto E; ViganĂ² MG; Passoni P; Zerbi A; Balzano G; Nicoletti R; Staudacher C; Di Carlo V
Cancer Invest; 2007; 25(7):594-8. PubMed ID: 17852117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]